Final Analysis of the Phase 1/2 Trial of Valoctocogene Roxaparvovec for Severe Haemophilia A.

Raheja P, Rangarajan S, Lester W, Madan B, Pierce GF, Symington E, Millar C, Osmond D, Li M, Chavele KM

DOI: 10.1111/hae.70284
Published: 2026 Jul-Aug
Container: Haemophilia : the official journal of the World Federation of Hemophilia
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/hae.70284,
  title = {Final Analysis of the Phase 1/2 Trial of Valoctocogene Roxaparvovec for Severe Haemophilia A.},
  author = {Raheja P and Rangarajan S and Lester W and Madan B and Pierce GF and Symington E and Millar C and Osmond D and Li M and Chavele KM},
  year = {2026},
  journal = {Haemophilia : the official journal of the World Federation of Hemophilia},
  doi = {10.1111/hae.70284},
  url = {https://doi.org/10.1111/hae.70284}
}

RIS

TY  - JOUR
TI  - Final Analysis of the Phase 1/2 Trial of Valoctocogene Roxaparvovec for Severe Haemophilia A.
AU  - Raheja P
AU  - Rangarajan S
AU  - Lester W
AU  - Madan B
AU  - Pierce GF
AU  - Symington E
AU  - Millar C
AU  - Osmond D
AU  - Li M
AU  - Chavele KM
PY  - 2026
JO  - Haemophilia : the official journal of the World Federation of Hemophilia
DO  - 10.1111/hae.70284
UR  - https://doi.org/10.1111/hae.70284
ER  -

APA

P, R., S, R., W, L., B, M., GF, P., E, S., C, M., D, O., M, L., & KM, C. (2026). Final Analysis of the Phase 1/2 Trial of Valoctocogene Roxaparvovec for Severe Haemophilia A.. Haemophilia : the official journal of the World Federation of Hemophilia. https://doi.org/10.1111/hae.70284

Source records

pubmed · retrieved 2026-09-26T10:49:25.894Z